| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 5651- | BNL, | Cisplatin, | Natural borneol sensitizes human glioma cells to cisplatin-induced apoptosis by triggering ROS-mediated oxidative damage and regulation of MAPKs and PI3K/AKT pathway |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 5652- | BNL, | Borneol promotes apoptosis of Human Glioma Cells through regulating HIF-1a expression via mTORC1/eIF4E pathway |
| - | vitro+vivo, | GBM, | NA |
| 5653- | BNL, | Borneol hinders the proliferation and induces apoptosis through the suppression of reactive oxygen species-mediated JAK1 and STAT-3 signaling in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 5663- | BNL, | Osthole/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP/PS1 transgenic mice |
| - | in-vivo, | AD, | NA |
| 3507- | Bor, | Boron inhibits apoptosis in hyperapoptosis condition: Acts by stabilizing the mitochondrial membrane and inhibiting matrix remodeling |
| 739- | Bor, | Borax regulates iron chaperone- and autophagy-mediated ferroptosis pathway in glioblastoma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HMC3 |
| 740- | Bor, | Anti-cancer effect of boron derivatives on small-cell lung cancer |
| - | in-vitro, | Lung, | DMS114 | - | in-vitro, | Nor, | MRC-5 |
| 742- | Bor, | In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | NA |
| 744- | Bor, | Borax affects cellular viability by inducing ER stress in hepatocellular carcinoma cells by targeting SLC12A5 |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 748- | Bor, | A Study on the Anticarcinogenic Effects of Calcium Fructoborate |
| - | in-vitro, | BC, | MDA-MB-231 |
| 749- | Bor, | Comparative effects of boric acid and calcium fructoborate on breast cancer cells |
| 738- | Bor, | Borax induces ferroptosis of glioblastoma by targeting HSPA5/NRF2/GPx4/GSH pathways |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | A172 | - | in-vitro, | Nor, | SVGp12 |
| 718- | Bor, | Boric Acid Exhibits Anticancer Properties in Human Endometrial Cancer Ishikawa Cells |
| - | in-vitro, | NA, | NA |
| 734- | Bor, | Boric Acid Affects the Expression of DNA Double-Strand Break Repair Factors in A549 Cells and A549 Cancer Stem Cells: An In Vitro Study |
| - | in-vitro, | Lung, | A549 |
| 726- | Bor, | Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open |
| - | Review, | NA, | NA |
| 724- | Bor, | Does Boric Acid Inhibit Cell Proliferation on MCF-7 and MDA-MB-231 Cells in Monolayer and Spheroid Cultures by Using Apoptosis Pathways? |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 2776- | Bos, | Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities |
| - | Review, | Var, | NA |
| 2767- | Bos, | The potential role of boswellic acids in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2773- | Bos, | Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer |
| - | Review, | Var, | NA |
| 2774- | Bos, | Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-453 |
| 1185- | Bos, | The journey of boswellic acids from synthesis to pharmacological activities |
| - | Review, | NA, | NA |
| 5697- | BRU, | Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma |
| - | in-vitro, | HNSCC, | NA |
| 2047- | Buty, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
| 3791- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | AD, | NA |
| 1652- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | Var, | NA |
| 5746- | CA, | Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 5750- | CA, | Exploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells |
| - | in-vitro, | MM, | NA |
| 5198- | CAP, | Capsaicin induces apoptosis by generating reactive oxygen species and disrupting mitochondrial transmembrane potential in human colon cancer cell lines |
| - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | Colo320 |
| 1262- | CAP, | Capsaicin Inhibits Proliferation and Induces Apoptosis in Breast Cancer by Down-Regulating FBI-1-Mediated NF-κB Pathway |
| - | vitro+vivo, | BC, | NA |
| 1517- | CAP, | Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1) |
| - | in-vitro, | Bladder, | TSGH8301 | - | in-vitro, | CRC, | T24/HTB-9 |
| 2012- | CAP, | Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways |
| - | NA, | OS, | MG63 |
| 2014- | CAP, | Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | HPDE-6 | - | in-vivo, | PC, | AsPC-1 |
| 2019- | CAP, | Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer |
| - | Review, | Var, | NA |
| 2020- | CAP, | Capsaicinoids and Their Effects on Cancer: The “Double-Edged Sword” Postulate from the Molecular Scale |
| - | Review, | Var, | NA |
| 1287- | CAR, | Carvacrol induces apoptosis in human breast cancer cells via Bcl-2/CytC signaling pathway |
| - | in-vitro, | BC, | HCC1937 |
| 1298- | CGA, | Chlorogenic acid regulates apoptosis and stem cell marker-related gene expression in A549 human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 4478- | Chit, | Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 1144- | CHr, | 8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | Nor, | HL7702 |
| 1145- | CHr, | Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways |
| - | in-vitro, | Cerv, | HeLa |
| 2804- | CHr, | Rad, | Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway |
| - | in-vitro, | CRC, | HT29 |
| 2805- | CHr, | Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC) |
| - | in-vitro, | ESCC, | KYSE150 | - | in-vivo, | ESCC, | NA |
| 2807- | CHr, | Evidence-based mechanistic role of chrysin towards protection of cardiac hypertrophy and fibrosis in rats |
| - | in-vivo, | Nor, | NA |
| 2780- | CHr, | Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review |
| - | Review, | Var, | NA |
| 2782- | CHr, | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 2783- | CHr, | Apoptotic Effects of Chrysin in Human Cancer Cell Lines |
| - | Review, | Var, | NA |
| 2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
| - | Review, | Var, | NA |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2787- | CHr, | Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics |
| - | Analysis, | Var, | MCF-7 |
| 2790- | CHr, | Chrysin: Pharmacological and therapeutic properties |
| - | Review, | Var, | NA |
| 1249- | CHr, | Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes |
| - | in-vitro, | CLL, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid